Olanzapine versus placebo in adolescents with schizophrenia

A 6-week, randomized, double-blind, placebo-controlled trial

Ludmila Kryzhanovskaya, S. Charles Schulz, Christopher McDougle, Jean Frazier, Ralf Dittmann, Carol Robertson-Plouch, Theresa Bauer, Wen Xu, Wei Wang, Janice Carlson, Mauricio Tohen, Ludmila A. Kryzhanovskaya

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Objective: To assess olanzapine's efficacy and tolerability in adolescents with schizophrenia. Method: One hundred seven inpatient and outpatient adolescents (olanzapine, n = 72, mean age 16.1 years; placebo, n = 35, mean age 16.3 years) with schizophrenia participated in this randomized (2:1), international, multisite, industry-sponsored trial. All patients met DSM-IV-TR criteria for schizophrenia, and they were treated for up to 6 weeks with flexible doses of olanzapine (2.5-20.0 mg/day) or placebo. Last-observation- carried-forward mean changes from baseline to endpoint on the anchored version of the Brief Psychiatric Rating Scale for Children, Clinical Global Impression Scale-Severity of Illness, and Positive and Negative Syndrome Scale (PANSS) were assessed. Results: More olanzapine-treated versus placebo-treated patients completed the trial (68.1 % versus 42.9%, p = .020). Compared with placebo-treated patients, olanzapine-treated adolescents had significantly greater improvement in Brief Psychiatric Rating Scale for Children total (p = .003), Clinical Global Impressions Scale-Severity of Illness (p = .004), PANSS total (p = .005), and PANSS positive scores (p = .002). Olanzapine-treated patients gained significantly more baseline-to-endpoint weight (4.3 kg versus 0.1 kg, p < .001). Significantly more olanzapine-treated versus placebo-treated patients gained 7% or greater of their body weight at any time during treatment (45.8% versus 14.7%, p = .002). Prolactin and triglyceride mean baseline-to-endpoint changes were significantly higher in olanzapine-treated versus placebo-treated adolescents. The incidence of treatment-emergent significant changes in fasting glucose, cholesterol, or triglycerides did not differ between the groups at endpoint, but significantly more olanzapine-treated patients had high triglycerides at any time during treatment. Conclusions: Olanzapine-treated adolescents with schizophrenia experienced significant symptom improvement. Significant increases in weight, triglycerides, uric acid, most liver function tests, and prolactin were observed during olanzapine treatment.

Original languageEnglish (US)
Pages (from-to)60-70
Number of pages11
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

olanzapine
Schizophrenia
Placebos
Triglycerides
Brief Psychiatric Rating Scale
Prolactin
Weights and Measures

Keywords

  • Efficacy
  • Olanzapine
  • Schizophrenia
  • Tolerability

Cite this

Olanzapine versus placebo in adolescents with schizophrenia : A 6-week, randomized, double-blind, placebo-controlled trial. / Kryzhanovskaya, Ludmila; Schulz, S. Charles; McDougle, Christopher; Frazier, Jean; Dittmann, Ralf; Robertson-Plouch, Carol; Bauer, Theresa; Xu, Wen; Wang, Wei; Carlson, Janice; Tohen, Mauricio; Kryzhanovskaya, Ludmila A.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 48, No. 1, 01.01.2009, p. 60-70.

Research output: Contribution to journalArticle

Kryzhanovskaya, L, Schulz, SC, McDougle, C, Frazier, J, Dittmann, R, Robertson-Plouch, C, Bauer, T, Xu, W, Wang, W, Carlson, J, Tohen, M & Kryzhanovskaya, LA 2009, 'Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 48, no. 1, pp. 60-70. https://doi.org/10.1097/CHI.0b013e3181900404
Kryzhanovskaya, Ludmila ; Schulz, S. Charles ; McDougle, Christopher ; Frazier, Jean ; Dittmann, Ralf ; Robertson-Plouch, Carol ; Bauer, Theresa ; Xu, Wen ; Wang, Wei ; Carlson, Janice ; Tohen, Mauricio ; Kryzhanovskaya, Ludmila A. / Olanzapine versus placebo in adolescents with schizophrenia : A 6-week, randomized, double-blind, placebo-controlled trial. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2009 ; Vol. 48, No. 1. pp. 60-70.
@article{0e3b10e5454a4be0853e63cbd3283df8,
title = "Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial",
abstract = "Objective: To assess olanzapine's efficacy and tolerability in adolescents with schizophrenia. Method: One hundred seven inpatient and outpatient adolescents (olanzapine, n = 72, mean age 16.1 years; placebo, n = 35, mean age 16.3 years) with schizophrenia participated in this randomized (2:1), international, multisite, industry-sponsored trial. All patients met DSM-IV-TR criteria for schizophrenia, and they were treated for up to 6 weeks with flexible doses of olanzapine (2.5-20.0 mg/day) or placebo. Last-observation- carried-forward mean changes from baseline to endpoint on the anchored version of the Brief Psychiatric Rating Scale for Children, Clinical Global Impression Scale-Severity of Illness, and Positive and Negative Syndrome Scale (PANSS) were assessed. Results: More olanzapine-treated versus placebo-treated patients completed the trial (68.1 {\%} versus 42.9{\%}, p = .020). Compared with placebo-treated patients, olanzapine-treated adolescents had significantly greater improvement in Brief Psychiatric Rating Scale for Children total (p = .003), Clinical Global Impressions Scale-Severity of Illness (p = .004), PANSS total (p = .005), and PANSS positive scores (p = .002). Olanzapine-treated patients gained significantly more baseline-to-endpoint weight (4.3 kg versus 0.1 kg, p < .001). Significantly more olanzapine-treated versus placebo-treated patients gained 7{\%} or greater of their body weight at any time during treatment (45.8{\%} versus 14.7{\%}, p = .002). Prolactin and triglyceride mean baseline-to-endpoint changes were significantly higher in olanzapine-treated versus placebo-treated adolescents. The incidence of treatment-emergent significant changes in fasting glucose, cholesterol, or triglycerides did not differ between the groups at endpoint, but significantly more olanzapine-treated patients had high triglycerides at any time during treatment. Conclusions: Olanzapine-treated adolescents with schizophrenia experienced significant symptom improvement. Significant increases in weight, triglycerides, uric acid, most liver function tests, and prolactin were observed during olanzapine treatment.",
keywords = "Efficacy, Olanzapine, Schizophrenia, Tolerability",
author = "Ludmila Kryzhanovskaya and Schulz, {S. Charles} and Christopher McDougle and Jean Frazier and Ralf Dittmann and Carol Robertson-Plouch and Theresa Bauer and Wen Xu and Wei Wang and Janice Carlson and Mauricio Tohen and Kryzhanovskaya, {Ludmila A.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1097/CHI.0b013e3181900404",
language = "English (US)",
volume = "48",
pages = "60--70",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Olanzapine versus placebo in adolescents with schizophrenia

T2 - A 6-week, randomized, double-blind, placebo-controlled trial

AU - Kryzhanovskaya, Ludmila

AU - Schulz, S. Charles

AU - McDougle, Christopher

AU - Frazier, Jean

AU - Dittmann, Ralf

AU - Robertson-Plouch, Carol

AU - Bauer, Theresa

AU - Xu, Wen

AU - Wang, Wei

AU - Carlson, Janice

AU - Tohen, Mauricio

AU - Kryzhanovskaya, Ludmila A.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Objective: To assess olanzapine's efficacy and tolerability in adolescents with schizophrenia. Method: One hundred seven inpatient and outpatient adolescents (olanzapine, n = 72, mean age 16.1 years; placebo, n = 35, mean age 16.3 years) with schizophrenia participated in this randomized (2:1), international, multisite, industry-sponsored trial. All patients met DSM-IV-TR criteria for schizophrenia, and they were treated for up to 6 weeks with flexible doses of olanzapine (2.5-20.0 mg/day) or placebo. Last-observation- carried-forward mean changes from baseline to endpoint on the anchored version of the Brief Psychiatric Rating Scale for Children, Clinical Global Impression Scale-Severity of Illness, and Positive and Negative Syndrome Scale (PANSS) were assessed. Results: More olanzapine-treated versus placebo-treated patients completed the trial (68.1 % versus 42.9%, p = .020). Compared with placebo-treated patients, olanzapine-treated adolescents had significantly greater improvement in Brief Psychiatric Rating Scale for Children total (p = .003), Clinical Global Impressions Scale-Severity of Illness (p = .004), PANSS total (p = .005), and PANSS positive scores (p = .002). Olanzapine-treated patients gained significantly more baseline-to-endpoint weight (4.3 kg versus 0.1 kg, p < .001). Significantly more olanzapine-treated versus placebo-treated patients gained 7% or greater of their body weight at any time during treatment (45.8% versus 14.7%, p = .002). Prolactin and triglyceride mean baseline-to-endpoint changes were significantly higher in olanzapine-treated versus placebo-treated adolescents. The incidence of treatment-emergent significant changes in fasting glucose, cholesterol, or triglycerides did not differ between the groups at endpoint, but significantly more olanzapine-treated patients had high triglycerides at any time during treatment. Conclusions: Olanzapine-treated adolescents with schizophrenia experienced significant symptom improvement. Significant increases in weight, triglycerides, uric acid, most liver function tests, and prolactin were observed during olanzapine treatment.

AB - Objective: To assess olanzapine's efficacy and tolerability in adolescents with schizophrenia. Method: One hundred seven inpatient and outpatient adolescents (olanzapine, n = 72, mean age 16.1 years; placebo, n = 35, mean age 16.3 years) with schizophrenia participated in this randomized (2:1), international, multisite, industry-sponsored trial. All patients met DSM-IV-TR criteria for schizophrenia, and they were treated for up to 6 weeks with flexible doses of olanzapine (2.5-20.0 mg/day) or placebo. Last-observation- carried-forward mean changes from baseline to endpoint on the anchored version of the Brief Psychiatric Rating Scale for Children, Clinical Global Impression Scale-Severity of Illness, and Positive and Negative Syndrome Scale (PANSS) were assessed. Results: More olanzapine-treated versus placebo-treated patients completed the trial (68.1 % versus 42.9%, p = .020). Compared with placebo-treated patients, olanzapine-treated adolescents had significantly greater improvement in Brief Psychiatric Rating Scale for Children total (p = .003), Clinical Global Impressions Scale-Severity of Illness (p = .004), PANSS total (p = .005), and PANSS positive scores (p = .002). Olanzapine-treated patients gained significantly more baseline-to-endpoint weight (4.3 kg versus 0.1 kg, p < .001). Significantly more olanzapine-treated versus placebo-treated patients gained 7% or greater of their body weight at any time during treatment (45.8% versus 14.7%, p = .002). Prolactin and triglyceride mean baseline-to-endpoint changes were significantly higher in olanzapine-treated versus placebo-treated adolescents. The incidence of treatment-emergent significant changes in fasting glucose, cholesterol, or triglycerides did not differ between the groups at endpoint, but significantly more olanzapine-treated patients had high triglycerides at any time during treatment. Conclusions: Olanzapine-treated adolescents with schizophrenia experienced significant symptom improvement. Significant increases in weight, triglycerides, uric acid, most liver function tests, and prolactin were observed during olanzapine treatment.

KW - Efficacy

KW - Olanzapine

KW - Schizophrenia

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=58249139362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249139362&partnerID=8YFLogxK

U2 - 10.1097/CHI.0b013e3181900404

DO - 10.1097/CHI.0b013e3181900404

M3 - Article

VL - 48

SP - 60

EP - 70

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 1

ER -